Century Therapeutics (IPSC) Projected to Post Earnings on Tuesday

Century Therapeutics (NASDAQ:IPSC) is anticipated to release its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect Century Therapeutics to post earnings of ($0.39) per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Friday, November 14, 2025 at 4:00 PM ET.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.38). Century Therapeutics had a negative return on equity of 11.53% and a negative net margin of 19.10%. On average, analysts expect Century Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Century Therapeutics Stock Performance

NASDAQ:IPSC opened at $0.58 on Monday. The stock has a 50-day simple moving average of $0.53 and a 200-day simple moving average of $0.55. The stock has a market cap of $50.37 million, a P/E ratio of -2.01 and a beta of 1.80. Century Therapeutics has a 1 year low of $0.34 and a 1 year high of $1.83.

Analysts Set New Price Targets

A number of analysts recently issued reports on IPSC shares. Wall Street Zen cut Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Century Therapeutics in a research report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $3.75.

Institutional Trading of Century Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new position in shares of Century Therapeutics during the 2nd quarter worth approximately $248,000. Raymond James Financial Inc. purchased a new position in shares of Century Therapeutics during the 2nd quarter worth approximately $51,000. Qube Research & Technologies Ltd purchased a new position in shares of Century Therapeutics during the 2nd quarter worth approximately $38,000. Marshall Wace LLP purchased a new position in shares of Century Therapeutics during the 2nd quarter worth approximately $78,000. Finally, Prudential Financial Inc. purchased a new position in shares of Century Therapeutics during the 2nd quarter worth approximately $25,000. 50.20% of the stock is owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.